Amarin (AMRN) Fair Value Target Cut at MKM Partners after Vascepa Doesn't Get NCE Status
Tweet Send to a Friend
MKM Partners analyst Jon LeCroy lowered his fair value target on Amarin Corporation (NASDAQ: AMRN) from $2.50 to $1.75 and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
